Galena Biopharma Inc (NASDAQ:GALE)’s stock on 02 June traded at beginning with a price of $2.20 and when day-trade ended the stock finally decreased -3.24% to end at $2.09. Galena Biopharma Inc (NASDAQ:GALE)’s showed weekly performance of 21.51%.
Galena Biopharma, Inc. (NASDAQ: GALE) announced the U.S. Food and Drug Administration (FDA) has designated NeuVax (nelipepimut-S), combined with recombinant granulocyte macrophage-colony stimulating factor (GM-CSF), as a Fast Track development program for the treatment of patients with early stage, node positive breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, following standard of care. Galenas PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical trial is an international, Phase 3 study to evaluate NeuVax plus GM-CSF versus placebo plus GM-CSF to prevent cancer recurrence.
Achaogen, Inc. (NASDAQ:AKAO) on Thursday its shares closed at $3.61. Achaogen, Inc. (NASDAQ:AKAO) monthly performance stands at 10.74% while its year to date performance is -37.11%.
Achaogen, Inc. (NASDAQ: AKAO) announced that it has achieved over 50 percent patient enrollment in its ongoing Phase 3 EPIC registration clinical trial of plazomicin. Achaogen is developing plazomicin, its lead product candidate, to treat serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
Gilead Sciences Inc. (NASDAQ:GILD) shares increased 0.16% on last trading day to close the day at $86.72. Company price to sale ratio is 3.50 and has 0.50% insider ownership. Gilead Sciences Inc. (NASDAQ:GILD) belongs to Healthcare sector.
Gilead Sciences, Inc. (NASDAQ:GILD) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for Epclusa®, an investigational, pan-genotypic, once-daily tablet containing the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400 mg and velpatasvir (VEL) 100 mg, an investigational pan-genotypic NS5A inhibitor, for the treatment of chronic hepatitis C virus (HCV) infection. The data included in the application support the use of Epclusa (SOF/VEL) in adults with all genotypes (GT1-6) of HCV infection.
On last trading day Cellectar Biosciences, Inc. (NASDAQ:CLRB) increased 23.49% to close at $3.89. CLRB is -90.00% away from its 52 week high and is moving 289.00% ahead of its 52 week low. Cellectar Biosciences, Inc. (NASDAQ:CLRB) return on equity (ROE) is -130.20%.
Cellectar Biosciences, Inc. (NASDAQ:CLRB) announces that the United States Patent and Trademark Office (“USPTO”) has issued U.S. Patent No. 9,339,564, which covers the treatment of cancer stem cells employing the company’s phospholipid drug conjugate (“PDC”) delivery platform technology; specifically, either of the company’s current PDC products, CLR 131 or CLR 125, in combination with external beam radiation. This patent, which provides intellectual property protection to at least June 2030, is based on one of multiple patent applications directed to the treatment of cancer stem cells.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Thursday closed at $15.71. Stock institutional ownership is 77.40% while insider ownership includes 7.70%. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) distance from 50-day simple moving average (SMA50) is -16.55%.
Sarepta Therapeutics Inc. (NASDAQ:SRPT), shares sunk in early-morning trade Thursday after the Food and Drug Administration announced guidance about compensation for patients with serious diseases granted access to not-yet-approved drugs. This expanded access or “compassionate use” policy has been in effect for years, but the FDA’s Thursday announcement also provided industry recommendations about how to charge for such drugs, saying a company “may recover only its direct costs associated with making the drug available to the patient… the sponsor may not charge for indirect costs, including administrative costs associated with providing an investigational drug.”
Galena Biopharma, Inc. (NASDAQ: GALE) announced the U.S. Food and Drug Administration (FDA) has designated NeuVax (nelipepimut-S), combined with recombinant granulocyte macrophage-colony stimulating factor (GM-CSF), as a Fast Track development program for the treatment of patients with early stage, node positive breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, following standard of care. Galenas PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical trial is an international, Phase 3 study to evaluate NeuVax plus GM-CSF versus placebo plus GM-CSF to prevent cancer recurrence.
Achaogen, Inc. (NASDAQ:AKAO) on Thursday its shares closed at $3.61. Achaogen, Inc. (NASDAQ:AKAO) monthly performance stands at 10.74% while its year to date performance is -37.11%.
Achaogen, Inc. (NASDAQ: AKAO) announced that it has achieved over 50 percent patient enrollment in its ongoing Phase 3 EPIC registration clinical trial of plazomicin. Achaogen is developing plazomicin, its lead product candidate, to treat serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
Gilead Sciences Inc. (NASDAQ:GILD) shares increased 0.16% on last trading day to close the day at $86.72. Company price to sale ratio is 3.50 and has 0.50% insider ownership. Gilead Sciences Inc. (NASDAQ:GILD) belongs to Healthcare sector.
Gilead Sciences, Inc. (NASDAQ:GILD) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for Epclusa®, an investigational, pan-genotypic, once-daily tablet containing the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400 mg and velpatasvir (VEL) 100 mg, an investigational pan-genotypic NS5A inhibitor, for the treatment of chronic hepatitis C virus (HCV) infection. The data included in the application support the use of Epclusa (SOF/VEL) in adults with all genotypes (GT1-6) of HCV infection.
On last trading day Cellectar Biosciences, Inc. (NASDAQ:CLRB) increased 23.49% to close at $3.89. CLRB is -90.00% away from its 52 week high and is moving 289.00% ahead of its 52 week low. Cellectar Biosciences, Inc. (NASDAQ:CLRB) return on equity (ROE) is -130.20%.
Cellectar Biosciences, Inc. (NASDAQ:CLRB) announces that the United States Patent and Trademark Office (“USPTO”) has issued U.S. Patent No. 9,339,564, which covers the treatment of cancer stem cells employing the company’s phospholipid drug conjugate (“PDC”) delivery platform technology; specifically, either of the company’s current PDC products, CLR 131 or CLR 125, in combination with external beam radiation. This patent, which provides intellectual property protection to at least June 2030, is based on one of multiple patent applications directed to the treatment of cancer stem cells.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Thursday closed at $15.71. Stock institutional ownership is 77.40% while insider ownership includes 7.70%. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) distance from 50-day simple moving average (SMA50) is -16.55%.
Sarepta Therapeutics Inc. (NASDAQ:SRPT), shares sunk in early-morning trade Thursday after the Food and Drug Administration announced guidance about compensation for patients with serious diseases granted access to not-yet-approved drugs. This expanded access or “compassionate use” policy has been in effect for years, but the FDA’s Thursday announcement also provided industry recommendations about how to charge for such drugs, saying a company “may recover only its direct costs associated with making the drug available to the patient… the sponsor may not charge for indirect costs, including administrative costs associated with providing an investigational drug.”
No comments:
Post a Comment